News Channels

14 Sep 2020 Neogene Therapeutics Raises $110 Million Series A Financing to Develop Next-Generation Fully Personalized Neo-Antigen T Cell Receptor (TCR) Therapies
14 Sep 2020 HiFiBiO Therapeutics Announces a Global Strategic Partnership With ABL Bio for the Co-Development of a SARS-CoV-2 Neutralizing Antibody
14 Sep 2020 Phase II trial results demonstrated improvement in cognition with BI 425809 in adult patients with schizophrenia
14 Sep 2020 Escient Pharmaceuticals Raises $77.5 Million Series B Round and Initiates a Phase 1/1b Clinical Trial of EP547, a MRGPR-targeted Therapy to Treat Cholestatic and Uremic Pruritus
14 Sep 2020 Seattle Genetics and Merck Announce Two Strategic Oncology Collaborations
14 Sep 2020 Gannex Filed US IND for Its NASH Drug ASC42, an FXR Agonist
14 Sep 2020 Alzprotect Forges Ahead with First Patients Enrolled in Phase 2a Study in Progressive Supranuclear Palsy (PSP)
14 Sep 2020 FDA Grants Dupixent® (dupilumab) Breakthrough Therapy Designation for Eosinophilic Esophagitis
14 Sep 2020 Novartis reports positive topline results from the first Phase III trial of Beovu® versus aflibercept in patients with diabetic macular edema (DME)
14 Sep 2020 Molecular Partners Completes GMP Manufacturing of Anti-COVID-19 DARPin® Candidate MP0420 for Clinical Use
14 Sep 2020 Gilead Sciences to Acquire Immunomedics
13 Sep 2020 Pfizer and BioNTech Propose Expansion of Pivotal COVID-19 Vaccine Trial
12 Sep 2020 COVID-19 vaccine AZD1222 clinical trials resumed in the UK
12 Sep 2020 Prasinezumab Slows Progression on Measures of Parkinson’s Disease in Phase 2 Study
12 Sep 2020 Keros Therapeutics Presents Results from Preclinical Studies Investigating KER-012 at the American Society for Bone and Mineral Research 2020 Annual Meeting
12 Sep 2020 Partner Therapeutics Announces Start of Phase 3 Portion of Clinical Study of Leukine® in Combination with Ipilumimab and Nivolumab in Front Line Treatment of Melanoma
12 Sep 2020 REYVOW™ (lasmiditan) C-V Demonstrated Pain Freedom from Migraine Attacks At 60 Minutes and Up to 48 Hours in New Phase 3 Study
12 Sep 2020 Neurocrine Biosciences and Voyager Therapeutics Present New Long-Term Three-Year Data Demonstrating that One-Time Treatment with an Investigational Gene Therapy Showed Sustained Improvement in Motor Function in Patients with Parkinson's Disease
12 Sep 2020 Neurocrine Biosciences Presents New Data Analyses Demonstrating Efficacy of FDA-Approved Once-Daily ONGENTYS® (opicapone) in Patients with Parkinson's Disease at the MDS Virtual Congress 2020
12 Sep 2020 Celltrion Announces Positive Interim Results From Phase I Trial of CT-P59, an Anti-COVID-19 Monoclonal Antibody Treatment Candidate

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up